Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 Assembly Biosciences, Inc. , a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a.
10.11.2023 - SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement .
Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond Now anticipate four development…
Gilead and Vir unite to find a ‘functional cure’ for hepatitis B
14th January 2021
Gilead Sciences and Vir Biotechnology have partnered to evaluate novel therapeutic combination strategies aimed at developing a ‘functional cure’ for chronic hepatitis B virus (HBV).
As part of the clinical collaboration, the companies are expecting to launch a Phase II trial evaluating combination therapies for both treatment-experienced and treatment-naïve people living with HBV.
This study will evaluate a number of combinations of Gilead’s investigational TLR-8 agonist selgantolimod, Vir’s small interfering ribonucleic acid (siRNA) candidate VIR-2218 and a marketed PD-1 antagonist.
Study participants who have previously received treatment for HBV may also be given Gilead’s Vemlidy (tenofovir alafenamide fumarate, TAF).